Week in Review: Sinopharm to Restructure with Private Capital

China National Pharmaceutical Group (Sinopharm), a State-Owned Enterprise and China’s largest drug maker, will be restructured with investment from private sources, adopting a hybrid ownership model; Guizhou Yibai Pharma will pay $128 million to acquire Tianjin Horus C&K Pharma; Morningside participated in a $55 million C funding for Aduro BioTech, a California cancer-immunotherapy company, and added Morningside’s Gerald Chan to its board; Cellular Biomedicine of California raised $10 million through a private placement to develop cell therapy products for the China market; Hamilton Thorne of Massachusetts was awarded CFDA approval for China marketing of its Lykos® laser, which is used in assisted reproduction procedures; and Beike Biotech filed with the CFDA for approval to use mesenchymal stem cells to treat lupus. More details.... Stock Symbols: (SHA: 600594) (NSDQ: CBMG) (TSX: HTL) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.